Brain

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical TrialNexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader…

2 weeks ago
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent GlioblastomaAlpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation…

2 weeks ago
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue RepairFibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued…

2 weeks ago
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START ProgramDenali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early…

2 weeks ago
Experience Onward Partners with Enthea to Expand Access to Psilocybin Treatment Through a Medical Tourism BenefitExperience Onward Partners with Enthea to Expand Access to Psilocybin Treatment Through a Medical Tourism Benefit

Experience Onward Partners with Enthea to Expand Access to Psilocybin Treatment Through a Medical Tourism Benefit

Portland, Oregon--(Newsfile Corp. - April 2, 2025) - Experience Onward, Oregon's premier state-licensed psilocybin service center, is proud to announce…

2 weeks ago
Wellform MD is first in Iowa to Offer Leading-edge Technology Using Brain Stimulation to Treat DepressionWellform MD is first in Iowa to Offer Leading-edge Technology Using Brain Stimulation to Treat Depression

Wellform MD is first in Iowa to Offer Leading-edge Technology Using Brain Stimulation to Treat Depression

Complimentary Launch Party April 24 to Showcase New Procedure ANKENY, Iowa, April 1, 2025 /PRNewswire/ -- Wellform MD, Des Moine's…

2 weeks ago
Leading Mental Health Provider SonderMind Expands Nationwide, Delivering High-Quality Mental Health Care in All 50 StatesLeading Mental Health Provider SonderMind Expands Nationwide, Delivering High-Quality Mental Health Care in All 50 States

Leading Mental Health Provider SonderMind Expands Nationwide, Delivering High-Quality Mental Health Care in All 50 States

DENVER, April 1, 2025 /PRNewswire/ -- SonderMind, a leader in comprehensive, personalized mental health care, announced it is now serving…

2 weeks ago
Preventing Underage Drinking Starts at Home: Talk It Out NC Empowers Parents and Children to Take Action Against Underage DrinkingPreventing Underage Drinking Starts at Home: Talk It Out NC Empowers Parents and Children to Take Action Against Underage Drinking

Preventing Underage Drinking Starts at Home: Talk It Out NC Empowers Parents and Children to Take Action Against Underage Drinking

Alcohol Awareness Month Highlights the Importance of Open Dialogue to Prevent Underage Drinking RALEIGH, N.C., April 1, 2025 /PRNewswire/ -- Talk…

2 weeks ago
REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual MeetingREMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting

REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting

Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second QuarterBRAINTREE, Mass.,…

2 weeks ago
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE TrialMoleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech,…

2 weeks ago
Show more Posts
Show previous Posts